Searchable abstracts of presentations at key conferences in endocrinology

ea0065oc2.2 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Investigating the role of AIP in pituitary tumourigenesis

Mistry Anisha , Solomou Antonia , Vignola Maria Lillina , Lim Chung Thong , Herincs Maria , Caimari Francisca , Costa Alejandro Ibanez , Begalli Federica , Gualtieri Angelica , Roncaroli Federico , Rizzoti Karine , Gaston-Massuet Carles , Korbonits Marta

Introduction: Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene predispose to growth hormone (GH, 90% of patients) or prolactin (PRL)-secreting tumours, with negligible number of patients with other pituitary tumour types. Animal models of acromegaly are scarce and Aip models have controversial data. Therefore we have generated two pituitary-specific Aip knockout mouse models to study the consequences of loss of AIP p...

ea0081rc6.8 | Rapid Communications 6: Endocrine-Related Cancer | ECE2022

Unveiling the role and contribution of CELF4 to the malignant features of PanNETs

Vioque Victor Garcia , Alors-Perez Emilia , Arevalo Sergio Pedraza , Agraz-Doblas Antonio , Blazquez-Encinas Ricardo , Blazquez-Encinas Ricardo , Moreno Montilla Maria Trinidad , Herrera-Martinez Aura D , Yubero Serrano Elena Maria , Ortega Salas Rosa , Serrano Blanch Raquel , Galvez Moreno Maria Angeles , Gahete , Manuel D , Costa Alejandro Ibanez , Luque Raul M , Castano Justo P

Pancreatic neuroendocrine tumors (PanNETs) are heterogeneous neoplasms with a relatively low but increasing incidence, mainly due to the difficulty in diagnosing this disease in its early stages. This notably complicates the treatment of this pathology and leads to a poor prognosis. One of the main reasons for this problem is the lack of adequate diagnostic biomarkers as well as effective therapeutic targets. In this sense, there is still a limited knowledge about alternative ...